|
Today's Headlines
The cost of treating people infected with the hepatitis C virus with newly approved therapies is likely to place a tremendous economic burden on the country's healthcare system, according to a study published in the Annals of Internal Medicine.
» MD Anderson study details
|
ADVERTISEMENT
Idiopathic Pulmonary Fibrosis (IPF)
IPF is the progressive formation of thick or scarred tissue in the lungs, resulting in loss of oxygen.
While there is currently no known cause, continued research seeks to find an answer,
alongside improved diagnosis and treatment options.
 Learn More
|
|
FDA has approved a new administration option for ticagrelor (Brilinta, AstraZeneca) in acute coronary syndrome patients. Brilinta has now become the first and only P2Y12 inhibitor with an FDA approval to be crushed and administered in water by swallowing or via nasogastric tube.
» Read more
|
Continuing Education
Last month and this month pharmacists will be able to learn about the latest developments in diabetes treatment and management. Pharmacists can earn up to 4 hours of CPE credit with two monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics. The goal of this month's activity is to discuss the recent updates of national U.S. guidelines for diabetes management, including hypertension and cholesterol management in patients with diabetes, in order to empower pharmacists in clinical decision-making.
Read/print the article: Click here
Take the test: Click here to log in with the Session Code 15DT16-TAJ88.
Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/
|
|
EDITOR'S PICK
FDA has approved use of Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus, DTaP-IPV (Quadracel, Sanofi Pasteur, the vaccines division of Sanofi), vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children aged 4 through 6 years. » Details
|
|
|
Like
Tweet
